Resultats globals: 1 registres trobats en 0.02 segons.
Articles, 1 registres trobats
Articles 1 registres trobats  
1.
17 p, 534.5 KB COAST : An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination with Oleclumab or Monalizumab in Patients with Unresectable, Stage III Non-Small-Cell Lung Cancer / Herbst, Roy S. (Yale Cancer Center. Smilow Cancer Hospital) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Barlesi, Fabrice (Gustave Roussy) ; Carcereny, Enric (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ; Chu, Quincy (Cross Cancer Institute) ; Monnet, Isabelle (Centre Hospitalier Intercommunal de Créteil) ; Sánchez Hernández, Alfredo (Consorci Hospitalari Provincial de Castelló) ; Dakhil, Shaker (Cancer Center of Kansas) ; Camidge, D (University of Colorado Anschutz Medical Campus) ; Winzer, Leanne (AstraZeneca) ; Soo-Hoo, Yee (AstraZeneca) ; Cooper, Zachary A. (AstraZeneca) ; Kumar, Rakesh (AstraZeneca) ; Bothos, John (AstraZeneca) ; Aggarwal, Charu (Abramson Cancer Center. University of Pennsylvania) ; Martinez-Marti, Alex (Vall d'Hebron Institut d'Oncologia)
PURPOSEDurvalumab significantly improves overall survival for patients with unresectable stage III non-small-cell lung cancer and no progression after concurrent chemoradiotherapy (cCRT). Building upon that standard of care, COAST is a phase II study of durvalumab alone or combined with the anti-CD73 monoclonal antibody oleclumab or anti-NKG2A monoclonal antibody monalizumab as consolidation therapy in this setting. [...]
2022 - 10.1200/JCO.22.00227
Journal of Clinical Oncology, Vol. 3 (january 2022) , p. JCO.22.00227  

Vegeu també: autors amb noms similars
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.